Literature DB >> 26713593

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.

R Marke1, J Havinga1, J Cloos2,3, M Demkes1, G Poelmans4,5,6, L Yuniati1, D van Ingen Schenau1, E Sonneveld7, E Waanders4, R Pieters8, R P Kuiper4, P M Hoogerbrugge8, G J L Kaspers2, F N van Leeuwen1, B Scheijen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26713593     DOI： 10.1038/leu.2015.359

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

Authors:  Petra S Bachmann; Rocco G Piazza; Mary E Janes; Nicholas C Wong; Carwyn Davies; Angela Mogavero; Vivek A Bhadri; Barbara Szymanska; Greta Geninson; Vera Magistroni; Giovanni Cazzaniga; Andrea Biondi; Diego Miranda-Saavedra; Berthold Göttgens; Richard Saffery; Jeffrey M Craig; Glenn M Marshall; Carlo Gambacorti-Passerini; John E Pimanda; Richard B Lock
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Authors:  R P Kuiper; E Waanders; V H J van der Velden; S V van Reijmersdal; R Venkatachalam; B Scheijen; E Sonneveld; J J M van Dongen; A J P Veerman; F N van Leeuwen; A Geurts van Kessel; P M Hoogerbrugge
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

3.  Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

Authors:  M Dördelmann; A Reiter; A Borkhardt; W D Ludwig; N Götz; S Viehmann; H Gadner; H Riehm; M Schrappe
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

4.  CREBBP mutations in relapsed acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Jinghui Zhang; Lawryn H Kasper; Stephanie Lerach; Debbie Payne-Turner; Letha A Phillips; Sue L Heatley; Linda Holmfeldt; J Racquel Collins-Underwood; Jing Ma; Kenneth H Buetow; Ching-Hon Pui; Sharyn D Baker; Paul K Brindle; James R Downing
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

Review 5.  Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis.

Authors:  Ronit Vogt Sionov; Rachel Spokoini; Shlomit Kfir-Erenfeld; Orly Cohen; Eitan Yefenof
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

6.  Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

Authors:  Erich Piovan; Jiyang Yu; Valeria Tosello; Daniel Herranz; Alberto Ambesi-Impiombato; Ana Carolina Da Silva; Marta Sanchez-Martin; Arianne Perez-Garcia; Isaura Rigo; Mireia Castillo; Stefano Indraccolo; Justin R Cross; Elisa de Stanchina; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Giuseppe Basso; Jules P Meijerink; Carlos Cordon-Cardo; Andrea Califano; Adolfo A Ferrando
Journal:  Cancer Cell       Date:  2013-11-27       Impact factor: 31.743

7.  In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.

Authors:  E Klumper; R Pieters; A J Veerman; D R Huismans; A H Loonen; K Hählen; G J Kaspers; E R van Wering; R Hartmann; G Henze
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

8.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.

Authors:  G J Kaspers; R Pieters; C H Van Zantwijk; E R Van Wering; A Van Der Does-Van Den Berg; A J Veerman
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

9.  Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation.

Authors:  Isabel Ferreirós-Vidal; Thomas Carroll; Benjamin Taylor; Anna Terry; Ziwei Liang; Ludovica Bruno; Gopuraja Dharmalingam; Sanjay Khadayate; Bradley S Cobb; Stephen T Smale; Mikhail Spivakov; Prashant Srivastava; Enrico Petretto; Amanda G Fisher; Matthias Merkenschlager
Journal:  Blood       Date:  2013-01-09       Impact factor: 22.113

10.  Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia.

Authors:  Ila Joshi; Toshimi Yoshida; Nilamani Jena; Xiaoqing Qi; Jiangwen Zhang; Richard A Van Etten; Katia Georgopoulos
Journal:  Nat Immunol       Date:  2014-02-09       Impact factor: 25.606
View more
  27 in total

1.  Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia.

Authors:  Takaya Moriyama; Shuguang Liu; Jing Li; Julia Meyer; Xujie Zhao; Wentao Yang; Youming Shao; Richard Heath; Aleš Hnízda; William L Carroll; Jun J Yang
Journal:  Mol Cancer Ther       Date:  2019-07-29       Impact factor: 6.261

2.  IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance.

Authors:  T Imamura; M Yano; D Asai; A Moriya-Saito; S-I Suenobu; D Hasegawa; T Deguchi; Y Hashii; H Kawasaki; H Hori; K Yumura-Yagi; J Hara; K Horibe; A Sato
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

Review 3.  Prognostic Impact of Somatic Copy Number Alterations in Childhood B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Beatriz Rosales-Rodríguez; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré; Haydeé Rosas-Vargas
Journal:  Curr Oncol Rep       Date:  2020-11-14       Impact factor: 5.075

4.  Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.

Authors:  Kathryn G Roberts; Yung-Li Yang; Debbie Payne-Turner; Wenwei Lin; Jacob K Files; Kirsten Dickerson; Zhaohui Gu; Jack Taunton; Laura J Janke; Taosheng Chen; Mignon L Loh; Stephen P Hunger; Charles G Mullighan
Journal:  Blood Adv       Date:  2017-08-30

Review 5.  IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Authors:  Martin Stanulla; Hélène Cavé; Anthony V Moorman
Journal:  Blood       Date:  2020-01-23       Impact factor: 22.113

6.  Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.

Authors:  Jason H Rogers; Rohit Gupta; Jaime M Reyes; Michael C Gundry; Geraldo Medrano; Anna Guzman; Rogelio Aguilar; Shannon E Conneely; Tidie Song; Cade Johnson; Sean Barnes; Carlo D D Cristobal; Kristen Kurtz; Lorenzo Brunetti; Margaret A Goodell; Rachel E Rau
Journal:  Blood Adv       Date:  2021-10-12

7.  Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.

Authors:  Bingqing Tang; Zihong Cai; Zhixiang Wang; Dainan Lin; Xianjun He; Qiuli Li; Xiaojie Liang; Kangyu Huang; Xuan Zhou; Ren Lin; Na Xu; Zhiping Fan; Fen Huang; Jing Sun; Xiaoli Liu; Qifa Liu; Hongsheng Zhou
Journal:  Bone Marrow Transplant       Date:  2022-09-02       Impact factor: 5.174

8.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.

Authors:  Chunhua Song; Zheng Ge; Yali Ding; Bi-Hua Tan; Dhimant Desai; Krishne Gowda; Shantu Amin; Raghavendra Gowda; Gavin P Robertson; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Zafer Gurel; Soumya Iyer; Pavan Kumar Dhanyamraju; Meixian Xiang; Yuka Imamura Kawasawa; Nathalia M Cury; José Andrés Yunes; Mary McGrath; Joe Schramm; Ruijun Su; Yiping Yang; Zhijun Zhao; Xiaoguang Lyu; Markus Muschen; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

9.  Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.

Authors:  Zheng Ge; Chunhua Song; Yali Ding; Bi-Hua Tan; Dhimant Desai; Arati Sharma; Raghavendra Gowda; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Soumya Iyer; Pavan Kumar Dhanyamraju; Yuka Imamura; Daniel Bogush; Yevgeniya Bamme; Yiping Yang; Mario Soliman; Shriya Kane; Elanora Dovat; Joseph Schramm; Tommy Hu; Mary McGrath; Zissis C Chroneos; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Leukemia       Date:  2021-02-02       Impact factor: 11.528

10.  Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols.

Authors:  Mirella Ampatzidou; Lina Florentin; Vassilios Papadakis; Georgios Paterakis; Marianna Tzanoudaki; Dimitra Bouzarelou; Stefanos I Papadhimitriou; Sophia Polychronopoulou
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.